Around 50% of asthma attacks and 30% of COPD attacks are "eosinophilic exacerbations" – which means they should respond to IL-5 inhibitors like Fasenra that specifically target this type of ...

Learn about COPD medications, including bronchodilators, steroids, and combination treatments. Understand how they work, their side effects, and ways to manage COPD effectively.

It’s notable that other attempts to reposition anti-inflammatory biologics for COPD – including IL-5 inhibitors, like GSK’s Nucala (mepolizumab) and AstraZeneca’s Fasenra (benralizumab ...

James Baker, Sophie Booth, Josiah Dungwa, Andrew Higham, Dave Singh, Simon Lea. Alveolar macrophage carbon is associated with COPD severity. ERJ Open Research, 2025; 00933-2024 DOI: 10.1183 ...

Walking is a fundamental activity for maintaining health. While numerous studies have assessed how much people with chronic obstructive pulmonary disease (COPD) walk, few have explored how they ...

COPD Assessment Test (CAT) total scores showed that respiratory symptom burden had a greater negative impact on health status and daily activities of those with undiagnosed asthma vs. healthy ...

Multifaceted remote interventions had a significant impact on patient outcomes in chronic obstructive pulmonary disease (COPD), a study published in the International Journal of Nursing Practice ...

Regeneron’s stock is having its worst day in 14 years after the failure of late-stage trial of its COPD treatment, after analysts had just placed a high probability of a positive result.

For COPD patients, the adage holds true: "the first way to get out of a hole is to quit digging one," said Christopher Mosher, MD, MHS, of Duke University in Durham, North Carolina.

Drummond, M. B., et al. (2025). Use of a Digital Inhaler to Assess COPD Disease Variability and Identify Impending Acute COPD Exacerbations: A Pilot Study. Chronic Obstructive Pulmonary Diseases ...

Tezepelumab has received an FDA breakthrough therapy designation as a maintenance treatment for patients with moderate to very severe COPD characterized by an eosinophilic phenotype, according to ...

Analyst Ratings Published 06/17/2025, 09:35 AM 0 Sanofi price target lowered to EUR8.40 at BofA on COPD trial results SNY 0.00% ...